KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EPS (Basic): 2009-2024

Historic EPS (Basic) for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$1.23.

  • Novavax's EPS (Basic) fell 64.47% to -$1.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.11, marking a year-over-year increase of 196.35%. This contributed to the annual value of -$1.23 for FY2024, which is 77.26% up from last year.
  • Latest data reveals that Novavax reported EPS (Basic) of -$1.23 as of FY2024, which was up 77.26% from -$5.41 recorded in FY2023.
  • In the past 5 years, Novavax's EPS (Basic) registered a high of -$1.23 during FY2024, and its lowest value of -$23.44 during FY2021.
  • Over the past 3 years, Novavax's median EPS (Basic) value was -$5.41 (recorded in 2023), while the average stood at -$5.02.
  • In the last 5 years, Novavax's EPS (Basic) plummeted by 222.42% in 2021 and then surged by 77.26% in 2024.
  • Novavax's EPS (Basic) (Yearly) stood at -$7.27 in 2020, then plummeted by 222.42% to -$23.44 in 2021, then skyrocketed by 64.08% to -$8.42 in 2022, then surged by 35.75% to -$5.41 in 2023, then spiked by 77.26% to -$1.23 in 2024.